fenofibrate has been researched along with torcetrapib in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aronow, WS | 1 |
Barone, FC; Brusq, JM; Grillot, DA; Hansen, MK; Issandou, M; Legos, JJ; McVey, MJ; White, RF | 1 |
2 other study(ies) available for fenofibrate and torcetrapib
Article | Year |
---|---|
Intensive statin treatment or combination therapy in high-risk patients.
Topics: Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Quinolines; Risk Factors | 2007 |
Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
Topics: Animals; Anticholesteremic Agents; Apolipoprotein B-100; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Dose-Response Relationship, Drug; Fenofibrate; Humans; Mice; Mice, Transgenic; PPAR alpha; Propionates; Quinolines; Thiazoles | 2010 |